Search

Displaying results 1371 - 1380 of 5261 in total
  1. Drug

    Benzonatate

    go.drugbank.com/drugs/DB00868
    Approved

    Benzonatate was approved by the FDA in 1958 under the market name Tessalon Perles. … [A189519] It works to reduce the activity of cough reflex by desensitizing the tissues of the lungs and pleura involved in the cough reflex.

    Synonyms: nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate
  2. Drug

    Berberine

    go.drugbank.com/drugs/DB04115
    ApprovedInvestigationalWithdrawn

    It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. … An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants.

  3. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    [A176810] Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. … It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.

  4. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.

  5. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    This class of antiviral drugs were the first direct acting antivirals approved but are associated with lower cure rates than newer drugs. … Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and [DB05521] but is classified as a second generation protease inhibitor.

  6. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. … [L10896] In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.

  7. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].

  8. Drug

    Flurandrenolide

    go.drugbank.com/drugs/DB00846
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)

  9. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    by the deficiency of alpha-galactosidase A. … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized

  10. Drug

    Pentastarch

    go.drugbank.com/drugs/DB09111
    ApprovedWithdrawn

    It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. … Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation.